1314867-11-2

Upstream product

• 2039-88-5 2-bromostyrene 
• 1314323-93-7 (R,R)-tert-butyl 2-(2-bromophenyl)cyclopropanecarboxylate 
• 928054-82-4 (1R,2R)-2-(2-bromo-phenyl)-1-cyclopropanecarboxylic acid ((R)-2-hydroxy-1-phenyl-ethyl)-amide 

Downstream Products

• 1314324-09-8 (1R,2S)-tert-butyl 2-(biphenyl-2-yl)cyclopropylcarbamate 
• 1314324-04-3 (1R,2S)-2-(2-bromophenyl)cyclopropanamine hydrochloride 
• 1314324-13-4 (1R,2S)-2-(biphenyl-2-yl)cyclopropanamine hydrochloride 
• 1314323-98-2 (1R,2S)-tert-butyl 2-(2-bromophenyl)cyclopropylcarbamate 

Relevant academic research and scientific papers

Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors

Asymmetric cyclopropanation of styrenes by tert-butyl diazoacetate followed by ester hydrolysis and Curtius rearrangement gave a series of tranylcypromine analogues as single enantiomers. The o,- m- and p-bromo analogues were all more active than tranylcypromine in a LSD1 enzyme assay. The m- and p-bromo analogues were micromolar growth inhibitors of the LNCaP prostate cancer cell line as were the corresponding biphenyl analogues prepared from the bromide by Suzuki crosscoupling.

5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS

This invention relates to compounds which modulate receptors of the 5-HT2 family of receptors, and particularly to compounds which modulate 5-HT2C receptors. Compounds of the invention include agonists and selective agonists for the 5-HT2C receptor. Compounds of the invention include selective agonists for the 5-HT2C receptor which exhibit significantly less or no agonist activity on the 5-HT2A receptor and/or the 5-HT2B receptor. Compounds of this invention are those of Formula I and pharmaceutically acceptable salts, esters and solvates (including hydrates) wherein variables are defined in the specification hereof.